Bexarotene combination therapy for patients with Sézary syndrome.
Ranki
Annamari
A
Department of Dermatology and Allergology, Helsinki University Hospital, Helsinki, Finland. Annamari.Ranki@hus.fi
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D000077610:Bexarotene; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D013974:Thyroxine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D013764:Tetrahydronaphthalenes; D000069059:Atorvastatin; D000077610:Bexarotene; D013974:Thyroxine